| 1. |
- Bunea, Ada-Ioana, et al.
(författare)
-
Micropatterned Carbon-on-Quartz Electrode Chips for Photocurrent Generation from Thylakoid Membranes
- 2018
-
Ingår i: ACS Applied Energy Materials. - : American Chemical Society (ACS). - 2574-0962. ; 1:7, s. 3313-3322
-
Tidskriftsartikel (refereegranskat)abstract
- Harvesting the energy generated by photosynthetic organisms through light-dependent reactions is a significant step toward a sustainable future energy supply. Thylakoid membranes are the site of photosynthesis, and thus particularly suited for developing photo-bioelectrochemical cells. Novel electrode materials and geometries could potentially improve the efficiency of energy harvesting using thylakoid membranes. For commercial applications, electrodes with large surface areas are needed. Photolithographic patterning of a photoresist, followed by pyrolysis, is a flexible and fast approach for the fabrication of carbon electrodes with tailored properties. In this work, electrode chips consisting of patterned carbon supported on quartz were designed and fabricated. The patterned electrode area is 1 cm2, and the measurement chamber footprint is 0.5 cm2, 1 order of magnitude larger than previously tested electrodes for thylakoid membrane immobilization. The use of a transparent substrate allows back-side illumination, protecting the bioelectrochemical system from the environment and vice versa. Two different mediators, monomeric ([Ru(NH3)6]3+) and polymeric ([Os(2,2′-bipyridine)2-poly(N-vinylimidazole)10Cl]+/2+), are used for evaluating photocurrent generation from thylakoid membranes with different electrode geometries. Current densities up to 71 μA cm–2 are measured upon illumination through the transparent electrode chip with solar simulated irradiance (1000 W m–2).
|
|
| 2. |
- Lund, Henrik, et al.
(författare)
-
The status of 4th generation district heating : Research and results
- 2018
-
Ingår i: Energy. - London : Elsevier. - 0360-5442 .- 1873-6785. ; 164, s. 147-159
-
Tidskriftsartikel (refereegranskat)abstract
- This review article presents a description of contemporary developments and findings related to the different elements needed in future 4th generation district heating systems (4GDH). Unlike the first three generations of district heating, the development of 4GDH involves meeting the challenge of more energy efficient buildings as well as the integration of district heating into a future smart energy system based on renewable energy sources. Following a review of recent 4GDH research, the article quantifies the costs and benefits of 4GDH in future sustainable energy systems. Costs involve an upgrade of heating systems and of the operation of the distribution grids, while benefits are lower grid losses, a better utilization of low-temperature heat sources and improved efficiency in the production compared to previous district heating systems. It is quantified how benefits exceed costs by a safe margin with the benefits of systems integration being the most important. © 2018 Elsevier Ltd
|
|
| 3. |
- Nielsen, Morten A., et al.
(författare)
-
Increased Galectin-9 Levels Correlate with Disease Activity in Patients with DMARD-Naïve Rheumatoid Arthritis and Modulate the Secretion of MCP-1 and IL-6 from Synovial Fibroblasts
- 2023
-
Ingår i: Cells. - : MDPI AG. - 2073-4409. ; 12:2
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Fibroblast-like synoviocytes (FLSs) are essential mediators in the expansive growth and invasiveness of rheumatoid synovitis, and patients with a fibroblastic-rich pauci-immune pathotype respond poorly to currently approved antirheumatic drugs. Galectin-9 (Gal-9) has been reported to directly modulate rheumatoid arthritis (RA) FLSs and to hold both pro- and anti-inflammatory properties. The objective of this study was to evaluate clinical and pathogenic aspects of Gal-9 in RA, combining national patient cohorts and cellular models. Methods: Soluble Gal-9 was measured in plasma from patients with newly diagnosed, treatment-naïve RA (n = 98). The disease activity score 28-joint count C-reactive protein (DAS28CRP) and total Sharp score were used to evaluate the disease course serially over a two-year period. Plasma and synovial fluid samples were examined for soluble Gal-9 in patients with established RA (n = 18). A protein array was established to identify Gal-9 binding partners in the extracellular matrix (ECM). Synovial fluid mononuclear cells (SFMCs), harvested from RA patients, were used to obtain synovial-fluid derived FLSs (SF-FLSs) (n = 7). FLSs from patients suffering from knee Osteoarthritis (OA) were collected from patients when undergoing joint replacement surgery (n = 5). Monocultures of SF-FLSs (n = 6) and autologous co-cultures of SF-FLSs and peripheral blood mononuclear cells (PBMCs) were cultured with and without a neutralizing anti-Gal-9 antibody (n = 7). The mono- and co-cultures were subsequently analyzed by flow cytometry, MTT assay, and ELISA. Results: Patients with early and established RA had persistently increased plasma levels of Gal-9 compared with healthy controls (HC). The plasma levels of Gal-9 were associated with disease activity and remained unaffected when adding a TNF-inhibitor to their standard treatment. Gal-9 levels were elevated in the synovial fluid of established RA patients with advanced disease, compared with corresponding plasma samples. Gal-9 adhered to fibronectin, laminin and thrombospondin, while not to interstitial collagens in the ECM protein array. In vitro, a neutralizing Gal-9 antibody decreased MCP-1 and IL-6 production from both RA FLSs and OA FLSs. In co-cultures of autologous RA FLSs and PBMCs, the neutralization of Gal-9 also decreased MCP-1 and IL-6 production, without affecting the proportion of inflammatory FLSs. Conclusions: In RA, pretreatment plasma Gal-9 levels in early RA were increased and correlated with clinical disease activity. Gal-9 levels remained increased despite a significant reduction in the disease activity score in patients with early RA. The in vitro neutralization of Gal-9 decreased both MCP-1 and IL-6 production in an inflammatory subset of RA FLSs. Collectively these findings indicate that the persistent overexpression of Gal-9 in RA may modulate synovial FLS activities and could be involved in the maintenance of subclinical disease activity in RA.
|
|
| 4. |
- Risberg, May Arna, et al.
(författare)
-
Arthroscopic surgical procedures versus sham surgery for patients with femoroacetabular impingement and/or labral tears : Study protocol for a randomized controlled trial (HIPARTI) and a prospective cohort study (HARP)
- 2018
-
Ingår i: Journal of Orthopaedic and Sports Physical Therapy. - : Journal of Orthopaedic & Sports Physical Therapy (JOSPT). - 0190-6011 .- 1938-1344. ; 48:4, s. 325-335
-
Tidskriftsartikel (refereegranskat)abstract
- STUDY DESIGN: Study protocol for a randomized controlled trial and a prospective cohort. BACKGROUND: The number of arthroscopic surgical procedures for patients with femoroacetabular impingement syndrome (FAIS) has significantly increased worldwide, but high-quality evidence of the effect of such interventions is lacking. OBJECTIVES: The primary objective will be to determine the efficacy of hip arthroscopic procedures compared to sham surgery on patient-reported outcomes for patients with FAIS (HIP ARThroscopy International [HIPARTI] Study). The secondary objective will be to evaluate prognostic factors for long-term outcome after arthroscopic surgical interventions in patients with FAIS (Hip ARthroscopy Prospective [HARP] Study). METHODS: The HIPARTI Study will include 140 patients and the HARP Study will include 100 patients. The international Hip Outcome Tool-33 will be the primary outcome measure at 1 year. Secondary outcome measures will be the Hip disability and Osteoarthritis Outcome Score, Arthritis Self-Efficacy Scale, fear of movement (Tampa Scale of Kinesiophobia), Patient-Specific Functional Scale, global rating of change score, and expectations. Other outcomes will include active hip range of motion, hip muscle strength tests, functional performance tests, as well as radiological assessments using radiographs and magnetic resonance imaging. CONCLUSION: To determine the true effect of surgery, beyond that of placebo, double-blinded placebo-controlled trials including sham surgery are needed. The HIPARTI Study will direct future evidence-based treatment of FAIS. Predictors for long-term development and progression of degenrative changes in the hip are also needed for this young patient group with FAIS; hence, responders and nonresponders to treatment could be determined.
|
|
